DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center – WO66-G609
Silver Spring, MD 20993-0002

FUJIFILM Sonosite, Inc.
% Mr. Mark Job
Responsible Third Party Official
Regulatory Technology Services LLC
1394 25th Street, NW
BUFFALO MN 55313

November 12, 2015

Re: K152983
Trade/Device Name: FUJIFILM SonoSite iViz Ultrasound System
Regulation Number: 21 CFR 892.1550
Regulation Name: Ultrasonic pulsed doppler imaging system
Regulatory Class: II
Product Code: IYN, IYO, ITX
Dated: October 8, 2015
Received: October 13, 2015

Dear Mr. Job:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Robert Ochs, Ph.D.
Director
Division of Radiological Health
Office of In Vitro Diagnostics
and Radiological Health
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120
Expiration Date: January 31, 2017
See PRA Statement below.

510(k) Number *(if known)*
~~TBD~~ K152983

Device Name
FUJIFILM SonoSite iViz Ultrasound System

Indications for Use *(Describe)*
The FUJIFILM SonoSite iViz Ultrasound System is a general purpose ultrasound system and non-continuous patient monitoring platform intended in clinical care by qualified physicians and healthcare professionals for evaluation by ultrasound imaging or fluid flow analysis of the human body. Specific clinical applications and exam types include:

Fetal - OB
Abdominal
Pediatric
Cardiac Adult
Cardiac Pediatric

Type of Use *(Select one or both, as applicable)*

☒ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Table 1.3-1: Diagnostic Ultrasound Indications for Use Form – FUJIFILM SonoSite iViz Ultrasound System

System:	FUJIFILM SonoSite iViz Ultrasound System						
Transducer:	N/A						
Intended Use:	Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:						
Clinical Application	**Mode of Operation**						
	B	M	PWD	CWD	Color Doppler	Combined (Spec.)	Other (Spec.)
Ophthalmic							
Fetal	N	N			N	B+M; B+CD	1-3
Abdominal	N	N			N	B+M; B+CD	1-3
Intra-operative (Abdominal organs and vascular)							
Intra-operative (Neuro.)							
Laparoscopic							
Pediatric	N	N			N	B+M; B+CD	1-3
Small Organ (breast, thyroid, testicles, prostate)							
Neonatal Cephalic							
Adult Cephalic							
Trans-rectal							
Trans-vaginal							
Trans-urethral							
Trans-esoph. (non-Card.)							
Musculo-skel. (Convent.)							
Musculo-skel. (Superfic.)							
Intra-luminal							
Other (spec.)							
Cardiac Adult	N	N			N	B+M; B+CD	1-3
Cardiac Pediatric	N	N			N	B+M; B+CD	1-3
Trans-esophageal (card.)							
Other (spec.)							
Peripheral vessel							
Other (spec.)							

N= new indication; P= previously cleared by FDA; E= added under this appendix

Additional Comments:

1: Color Doppler includes Power/Velocity/Variance
2: Tissue Harmonic Imaging (THI)
3: SonoHD3 Imaging (Speckle Reduction)

Prescription Use (Per 21 CFR 801.109)

Table 1.3-2: Diagnostic Ultrasound Indications for Use Form – P21v/5-1 Transducer

System:	FUJIFILM SonoSite iViz Ultrasound System						
Transducer:	P21v/5-1 MHz Transducer						
Intended Use:	Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:						
Clinical Application	**Mode of Operation**						
	B	M	PWD	CWD	Color Doppler	Combined (Spec.)	Other (Spec.)
Ophthalmic							
Fetal	N	N			N	B+M; B+CD	1-3
Abdominal	N	N			N	B+M; B+CD	1-3
Intra-operative (Abdominal organs and vascular)							
Intra-operative (Neuro.)							
Laparoscopic							
Pediatric	N	N			N	B+M; B+CD	1-3
Small Organ (breast, thyroid, testicles, prostate)							
Neonatal Cephalic							
Adult Cephalic							
Trans-rectal							
Trans-vaginal							
Trans-urethral							
Trans-esoph. (non-Card.)							
Musculo-skel. (Convent.)							
Musculo-skel. (Superfic.)							
Intra-luminal							
Other (spec.)							
Cardiac Adult	N	N			N	B+M; B+CD	1-3
Cardiac Pediatric	N	N			N	B+M; B+CD	1-3
Trans-esophageal (card.)							
Other (spec.)							
Peripheral vessel							
Other (spec.)							

N= new indication; P= previously cleared by FDA; E= added under this appendix

Additional Comments:

1: Color Doppler includes Power/Velocity/Variance
2: Tissue Harmonic Imaging (THI)
3: SonoHD3 Imaging (Speckle Reduction)

Prescription Use (Per 21 CFR 801.109)

510(K) Summary

This summary of safety and effectiveness is provided as part of this Premarket Notification in compliance with 21 CFR, Part 807, Subpart E, Section 807.92.

1) Submitter's name, address, telephone number, contact person:

FUJIFILM SonoSite, Inc.
21919 30th Drive SE
Bothell, WA 98021-3904

Corresponding Official:	Patricia Liau
	Manager, Regulatory Affairs
E-mail:	Patricia.Liau@sonosite.com
Telephone:	(425) 951-6870
Facsimile:	(425) 951-1201
Date prepared:	September 28, 2015

2) Name of the device, including the trade or proprietary name if applicable, the common or usual name, and the classification name, if known:

Common/ Usual Name

Diagnostic Ultrasound System with Accessories

Proprietary Name

SonoSite iViz Ultrasound System *(subject to change)*

Classification Names

Name	FR Number	Product Code
Ultrasonic Pulsed Doppler Imaging System	892.1550	90-IYN
Ultrasonic Pulsed Echo Imaging System	892.1560	90-IYO
Diagnostic Ultrasound Transducer	892.1570	90-ITX

3) Identification of the predicate or legally marketed device:

SonoSite Edge Ultrasound System	K133454
Philips Nuvis Ultrasound System	K133833

4) Device Description:

The SonoSite iViz Ultrasound System is a highly featured, general purpose, software controlled, diagnostic ultrasound system used to acquire and display high-resolution, real-time ultrasound data through multiple imaging modes. iViz is a custom fabricated digital electronic handheld tablet that is highly portable, battery-operated, and consists of an active transducer that connects to and is controlled by the tablet. iViz supports Bluetooth and wireless network connectivity for image transfer and over-the-air (OTA) software updates.

5) Intended Use:

The FUJIFILM SonoSite iViz Ultrasound System is a general purpose ultrasound system and non-

continuous patient monitoring platform intended in clinical care by qualified physicians and healthcare professionals for evaluation by ultrasound imaging or fluid flow analysis of the human body. Specific clinical applications and exam types include:

Fetal - OB
Abdominal
Pediatric
Cardiac Adult
Cardiac Pediatric

6) Technological Characteristics:

SonoSite iViz and Edge, and Philips Nuvis Ultrasound Systems are Track 3 devices that employ the same fundamental scientific technology. A comparison table is provided below.

Feature	SonoSite iViz Ultrasound System (This submission)	SonoSite Edge Ultrasound System (K133454)	Philips Nuvis Ultrasound System (K133833)
Intended Use	Diagnostic ultrasound imaging or fluid flow analysis of the human body	Diagnostic ultrasound imaging or fluid flow analysis of the human body	Diagnostic ultrasound imaging or fluid flow analysis of the human body
Indications for Use	Fetal – OB Abdominal Pediatric Cardiac Adult Cardiac Pediatric	Opthalmic Fetal – OB/GYN Abdominal Intraoperative (abdominal organs and vascular) Intra-operative (Neuro.) Pediatric Small Organ (breast, thyroid, testicle, prostate) Neonatal Cephalic Adult Cephalic Trans-Rectal Trans-Vaginal Musculo-skeletal (Conventional) Musculo-skeletal (Superficial) Cardiac Adult Cardiac Pediatric Trans-esophageal (cardiac) Peripheral Vessel Needle guidance	Fetal – OB Abdominal Other (Urology) Other (Gynecology) Other (Fetal Echo)
Transducer Types	Phased Array	Linear Array Curved Linear Array Intracavitary Phased Array Static Probes Trans-esophageal	Curved Linear Array
Transducer Frequency	1.0 – 5.0 MHz	1.0 – 15.0 MHz	2.0 – 5.0 MHz
Modes of Operation	B-mode Grayscale Imaging Tissue Harmonic Imaging M-mode Color M-Mode Color Power Doppler Zoom Combination Modes SonoHD3 Noise Reduction Velocity Color Doppler	B-mode Grayscale Imaging Tissue Harmonic Imaging M-mode Color M-Mode Color Power Doppler Zoom Combination Modes Pulsed Wave (PW) Doppler Continuous Wave (CW) Doppler SonoHD2 Noise Reduction SonoMB/MBe Image Compounding Steered CW Doppler Velocity Color Doppler Tissue Doppler Imaging (TDI)	B-mode Grayscale Imaging Color Power Doppler Combination Modes Velocity Color Doppler

Feature	SonoSite iViz Ultrasound System (This submission)	SonoSite Edge Ultrasound System (K133454)	Philips Nuvis Ultrasound System (K133833)
PW Doppler	Not available	Available	Not available
CW Doppler	Not available	Available	Not available
Patient Contact Materials	**Transducers:** Polysulfone UDEL P1700 Poly-Vinyl-Chloride (PVC) Silicone Rubber	**Transducers:** Acrylonitrile-butadien-styrene (ABS) Cycoloy Dow Medical Adhesive, Type A Epoxy paste adhesive Polyethylene (PE) Ionomer Polyetheretherketone (PEEK) Polysulfone UDEL P1700 Polyurethane Poly-Vinyl-Chloride (PVC) Silicone RTV Adhesive Silicone Rubber Urethane **Needle Guides:** Acetal copolymer Acrylonitrile-butadien-styrene (ABS)	Information not publicly available
System Characteristics	**iViz:** Handheld tablet 7", 1920 x 1200 pixels LCD Operating system: Android iViz ultrasound software running as an "app" on tablet System operates via battery Wireless 802.11 support for image transfer and over-the-air (OTA) software updates	**Edge:** Handheld display and control 12.1", 800 x 600 pixels, LCD Operating system: Windows CE System operates via battery or AC power Wireless 802.11 support for image transfer	**Nuvis:** Handheld tablet (COTS Nexus 7) 7", 1280 x 800 pixels LCD Operating system: Android Nuvis ultrasound software running as an "app" on COTS tablet System operates via battery Wireless 802.11 support for image transfer (non-DICOM)
510(k) Track	Track 3	Track 3	Track 3

7) Determination of Substantial Equivalence:

Summary of Non-Clinical Tests:
The iViz Ultrasound System has been evaluated for electrical, thermal, mechanical, and EMC safety. Additionally, cleaning/disinfection, biocompatibility, and acoustic output have been evaluated, and the device has been found to conform to applicable mandatory medical device safety standards. Assurance of quality was established by employing the following elements of product development but were not limited to: Design Phase Reviews, Risk Assessment, Requirements Development, and Verification and Validation.

The iViz Ultrasound System is designed to comply with the following FDA recognized standards.

Reference No.	Title
ISO 10993-1	AAMI / ANSI / ISO 10993-1:2009/(R)2013, Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process
IEC 60601-1	AAMI / ANSI ES60601-1:2005/(R)2012 and A1:2012,, C1:2009/(R)2012 and A2:2010/(R)2012 (Consolidated Text) Medical electrical equipment - Part 1: General requirements for basic safety and essential performance (IEC 60601-1:2005, MOD)
IEC 60601-1-2	AAMI / ANSI / IEC 60601-1-2:2007(R)2012, Medical electrical equipment – Part 1-2: General requirements for basic safety and essential performance - Collateral standard: Electromagnetic compatibility - Requirements and tests (Edition 3)
IEC 60601-1-6	IEC 60601-1-6 Edition 3.1 2013-10, Medical electrical equipment – Part 1-6: General requirements for basic safety and essential performance - Collateral standard: Usability
IEC 60601-2-37	IEC 60601-2-37:2007 Edition 2.0 2007-08, Medical electrical equipment – Part 2-37: Particular requirements for the basic safety and essential performance of ultrasonic

Reference No.	Title
	medical diagnostic and monitoring equipment
IEC 62304	AAMI / ANSI / IEC 62304:2006, Medical device software - Software life cycle processes
IEC 62359	IEC 62359 Edition 2.0 2010-10-10, Ultrasonics – Field characterization – Test methods for the determination of thermal and mechanical indices related to medical diagnostic ultrasonic fields [Including: Technical corrigendum 1 (2011)]
ISO 14971	ISO 14971:2007, Medical devices - Application of risk management to medical devices
NEMA UD 2-2004	Acoustic Output Measurement Standard for Diagnostic Ultrasound Equipment

Summary of Clinical Tests:
The iViz Ultrasound System and transducers, subject of this submission, did not require clinical studies to support the determination of substantial equivalence.

8) Conclusion:

Intended uses and other key features are consistent with traditional clinical practice and FDA guidance. The iViz system and predicates meet FDA requirements for Track 3 devices, share indications for use, have biosafety equivalence, and conform to applicable electromedical device safety standards. FUJIFILM SonoSite, Inc. believes that the iViz Ultrasound System is substantially equivalent with regard to safety and effectiveness to the predicate devices.